CC2574‐P‐174.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 45, chronic lymphocytic leukemia (any stage); concomitant therapy: other
Interventions	drug = Epoetin alpha dose = 150 IU/kg sc TIW hb‐target = Hct 38%‐40% planned ESA duration = 12 weeks
Outcomes	Primary: Hct; secondary: Hb, transfusion, QoL, safety
Notes	study number = 60584
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer generated
Allocation concealment?	Unclear risk	no description